AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovarian cancer drug.
Subscribe to TheStreet's free daily newsletter 💰💵 That is why the market saw AbbVie make a number of acquisitions to expand ...
13don MSN
Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.
Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...
Argus Research analyst Jasper Hellweg maintained a Buy rating on AbbVie (ABBV – Research Report) on January 31. The company’s shares opened ...
In a report released yesterday, Vamil Divan from Guggenheim reiterated a Buy rating on AbbVie (ABBV – Research Report), with a price target of ...
AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.
Let's decide whether AbbVie is a buy. In the pharmaceutical business ... $10.1 billion for ImmunoGen, and $8.7 billion for Cerevel Therapeutics.
Let's decide whether AbbVie is a buy. In the pharmaceutical business ... $10.1 billion for ImmunoGen, and $8.7 billion for Cerevel Therapeutics. The company's ratio of debt to EBITDA (earnings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results